What next for the AstraZeneca share price?

With rising revenue and increased sales forecasts, what comes next for AstraZeneca shares?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The pharmaceutical giant AstraZeneca (LSE: AZN) saw some strong results last week, helping to boost its share price toward record highs. As a contrarian investor, I generally see this as a big no-no for investing in a stock, however this truth only holds if we think the number is not actually going to get any higher.

The numbers

Last week the company lifted its sales forecast for the second time this year, and announced rising revenue for the fifth consecutive quarter – both of which I see as signs particularly good in the pharmaceutical sector, where failed drug trials and the availability of cheap generic alternatives, can take their toll.

Sales of its new medicines have been going strong, climbing 64% in the quarter; with notable sales of its oncology drugs – a key competitive area for AstraZeneca – seeing sales climb 45% on a constant currency basis.

Meanwhile the emerging markets arena, which for Big Pharma is where the biggest issues with cheap generic alternatives, both illegal and out of patent, take place, actually grew by 90% for AstraZeneca.

In a statement alongside the results, CEO Pascal Soriot emphasised how the latest numbers show the breadth of Astra’s resurgence – both geographically and on a product basis – another key investment point in my opinion.

What about the share price?

Though offering the stock a temporary boost, I think these numbers also indicate AstraZeneca’s strength over the long term.

For a start, the strong sales performance of its oncology drugs is a sign of its strategy in that field. While most of the big pharmaceutical names concentrate their efforts at Stage 4 levels of cancer, Astra focuses instead on early treatment and detection, carving out a niche for itself.

The company has also been making good headway in China, working with the government and local hospitals to gain a strong base for selling its drugs at fair prices, competing with generic alternatives. Mr Soriot did warn however that he expects sales in China to slow as changes in the way the country purchases drugs will make it more difficult for some of Astra’s medicines to maintain a foothold.

With this in mind, the main area impacting the share price going forward may not in fact be the underlying strength of the company, but rather market expectations. When companies put in such good performance, investors begin to expect greater and greater things.

It is strange, perhaps, that strong financial numbers are in and of themselves not considered good by investors, unless they are better than the ‘expected’ figures given by a particular analyst or talking head (company guidance itself is usually kept realistic to avoid large share movements).

Of course, this is because the stock will already be factoring in the expected numbers, but it still seems strange that a company with growing profits will see its share price hit. Unfortunately for AstraZeneca, I expect this may be a trap it falls into.

Its share price is not cheap, and though over the long term it seems to be a strong investment, any investors looking to get out in the next year or two may see more volatility. As a long-term Buy however, I still think Astra will see its share price climb.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Karl has shares in AstraZeneca. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After crashing 45% in October, should I buy this FTSE 250 share for my Stocks and Shares ISA?

Roland Head explains why he’s tempted to add this risky FTSE 250 turnaround share to his Stocks and Shares ISA…

Read more »

Investing Articles

Could I use a stock market crash to turn £20k into half a mil in just over a decade?

A stock market crash might sound terrifying to some but it can also present a once-in-a-lifetime opportunity to accumulate generational…

Read more »

Investing Articles

Recently released: October’s small-cap stock recommendation [PREMIUM PICKS]

We believe the UK small-cap market offers a myriad of opportunities across a wide range of different businesses and industries.

Read more »

Investing Articles

Here’s how a Stocks and Shares ISA and Lifetime ISA could supercharge my wealth!

Individual Savings Accounts (ISAs) can help UK share investors take their earnings to the next level. And their importance is…

Read more »

A person holding onto a fan of twenty pound notes
Investing Articles

A high-yield dividend ETF and an investment trust to consider this November!

Investors wanting to boost their passive income could benefit from investigating these high-yield funds and trusts, says Royston Wild.

Read more »

Investing Articles

2 of my favourite, cheap FTSE 100 growth shares this November!

These FTSE 100 growth shares could be great long-term picks to consider, reckons Royston Wild. At current prices he thinks…

Read more »

Investing Articles

Up 26%, can the BT share price really push higher still?

The BT share price has surged on several catalysts in 2024, but there’s evidence to suggest that the stock could…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

What are the best dividend shares to buy right now?

As shares in B&M European Value Retail have fallen, the dividend yield has reached a 10-year high. Should investors be…

Read more »